Wednesday, December 14, 2016

BRIEF-Bluebird Bio announces treatment of first patient with thalassemia drug

* Bluebird Bio Inc says also moving forward with plans to

initiate northstar-3 (hgb-212), a phase 3 trial of lentiglobin

drug product

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)